RxDoctor Payments Data

Melissa Bradley

Adult Health · Exton, PANPI 1083858054

Payments from drug & device makers

$458in general payments, 2019–2025

Across 18 payments — averaging $25.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$137
  • Phathom Pharmaceuticals, Inc.$111
  • Boehringer Ingelheim$100
  • Ipsen Biopharmaceuticals, Inc$44
  • AbbVie$27
  • Gilead$26
  • plus $14 from 1 others

What the payments were for

  • Food & beverage$458100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$458 in reported general payments places this provider in the 50th percentile of 899 adult health providers in Pennsylvania.

See all adult health providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$50,390
Medicare patients
321
Services billed
1,019

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide37$46,386
MounjaroTirzepatide24$29,422
EliquisApixaban23$21,728
JardianceEmpagliflozin12$15,232
Advair DiskusFluticasone Propion/Salmeterol11$2,040
Atorvastatin Calcium157$1,415
Valsartan23$1,299
Rosuvastatin Calcium127$1,263
Boostrix TdapDiphth,pertuss(Acell),tet Vac18$1,261
Albuterol Sulfate HfaAlbuterol Sulfate52$1,155
Levothyroxine Sodium130$1,122
SynthroidLevothyroxine Sodium21$1,011
Bupropion XlBupropion Hcl18$974
Metoprolol Succinate57$973
Fluticasone-SalmeterolFluticasone Propion/Salmeterol15$784

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$137$46,38637 claims
Lilly USA, LLCMounjaro$14$29,42224 claims
Boehringer IngelheimJardiance$100$15,23212 claims
AbbVieSynthroid$27$1,01121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 899 adult health providers in Pennsylvania.

Other adult health in Exton

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →